Limiting the immunomodulator comedication to IBD patients with immunogenic LOR to the anti-TNF monotherapy might be an alternative approach to initial combination therapy for all patients, especially when the risk of malignancy or infection is relevant. This evidence concerns the gene TNF and inflammatory bowel disease.